Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Taurochenodeoxycholate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 3/20 | 0.70 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.70 |
| ▸ | NR3C1 known ✓ | P04150 | 1/20 | 0.69 |
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.84 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.84 |
| ▸ | SLC10A2 | Q12908 | 3/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.84 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.84 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.84 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.84 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | RAB9A | P51151 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | BLM | P54132 | 1/20 | 0.82 |
| ▸ | SLC10A1 | Q14973 | 3/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taurochenodeoxycholate SCHEMBL29461502 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 | |
| Taurochenodeoxycholate SCHEMBL29481129 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 | |
| Taurochenodeoxycholate SCHEMBL60947 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 | |
| Taurochenodeoxycholate SCHEMBL9222712 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 | |
| Taurochenodeoxycholate SCHEMBL10695689 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 | |
| Taurochenodeoxycholate SCHEMBL20261732 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 | |
| Taurochenodeoxycholate SCHEMBL10695686 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 | |
| Taurochenodeoxycholate SCHEMBL30341854 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 | |
| Taurochenodeoxycholate SCHEMBL9070400 | 0.98 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 | |
| Taurochenodeoxycholate SCHEMBL9068987 | 0.98 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 560 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651897-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | Syntis Bio, Inc. (US) | 2025-11-26 | — | — | EP | claimed |
| WO-2025102424-A1 | COLD STORAGE SOLUTION AND USE THEREOF IN REDUCING ISCHEMIA-REPERFUSION INJURY OF CELLS, TISSUES, OR ORGANS | 中山大学附属第三医院 | 2025-05-22 | — | — | WO | claimed |
| CN-119097630-A | Liver protecting agent containing sodium ursodeoxycholate taurine and preparation method thereof | 湖北天安宏泰生物科技有限公司 | 2024-12-10 | — | — | CN | claimed |
| WO-2024230827-A1 | POLYMER LIPID COMPOUNDS, AND COMPOSITIONS, PREPARATION AND USE THEREOF | 苏州慧疗生物医药科技有限公司 | 2024-11-14 | — | — | WO | claimed |
| US-20240261411-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | SYNTIS BIO, INC. | 2024-08-08 | — | — | US | claimed |
| WO-2024155958-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | SYNTIS BIO, INC. (US) | 2024-07-25 | — | — | WO | claimed |
| CN-117581858-A | Cold preservation solution and application thereof in reducing ischemia reperfusion injury of cells, tissues or organs | 中山大学附属第三医院 | 2024-02-23 | — | — | CN | claimed |
| CN-115286678-B | Purification method of bioconversion tauroursodeoxycholic acid | 江苏邦泽生物医药技术股份有限公司 | 2024-02-23 | — | — | CN | claimed |
| US-20240058454-A1 | BIOLOGICAL DELIVERY SYSTEMS | PARTICELLA INC (US) | 2024-02-22 | — | — | US | claimed |
| CN-117241780-A | Biological delivery system | 帕帝塞拉公司 | 2023-12-15 | — | — | CN | claimed |
| EP-1608392-A4 | PAPANICOLAU STAINING PROCESS | CYTYC CORP (US) | 2007-09-05 | — | — | EP | claimed |
| US-7186522-B2 | Using detergents to reduce artifacts during staining of biological samples; medical diagnostics and cervical cancer | CYTYC CORPORATION (US) | 2007-03-06 | — | — | US | claimed |
| US-20070003998-A1 | Papanicolau staining process | THIRD WAVE TECHNOLOGIES, INC. | 2007-01-04 | — | — | US | claimed |
| CN-1764469-A | Papanicolaou staining method | CYTYC CORP (US) | 2006-04-26 | — | — | CN | claimed |
| EP-1608392-A2 | PAPANICOLAU STAINING PROCESS | Cytyc Corporation (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050145490-A1 | Reagent includes an oxidoreductase that reacts with the blood component (glucose,lactic acid, uric acid, cholesterol etc.) and potassium ferricyanide mediator, detecting a redox current generated by the redox reaction by the working electrode and the counter electrode; correct an effect of a hematocrit | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2005-07-07 | — | — | US | claimed |
| WO-2004086945-A2 | PAPANICOLAU STAINING PROCESS | CYTYC CORPORATION (US) | 2004-10-14 | — | — | WO | claimed |
| US-20040191854-A1 | Papanicolau staining process | CYTYC CORPORATION | 2004-09-30 | — | — | US | claimed |
| US-5578304-A | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof | DIGESTIVE CARE INC. (US) | 1996-11-26 | — | — | US | claimed |
| US-5460812-A | Comprising buffer, disintegrant, adhesive polymer and acid resistant polymeric coating; for digestion, liver disorders, cystic fibrosis, dissolving gallstones | DIGESTIVE CARE INC. (US) | 1995-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261411-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | FABP2, SLC10A2, FABP6 | CA1 1690/4885CA2 1908/4885NR3C1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.